Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Plain-language summary

This study evaluates the combination of hypomethylating drugs with a dendritic cell (DC) vaccine in elderly patients with myelodysplastic syndrome. It enrolls patients older than 60 with normal heart, liver, and kidney function who are unsuitable for or unwilling to have a stem cell transplant. It is a Phase 1 study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Recruiting

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Intervention

DC vaccine

Start date

7/1/2021

Estimated completion

7/1/2026

Countries

China

Related genes

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. elderly MDS patients;
2. aged more than 60 years old, general condition, ECOG score less than 1;
3. normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol / L; serum creatinine ≤ 150 umol / L;
4. patients are unsuitable or unwilling to receive hematopoietic stem cell transplantation;
5. subjects sign informed consent.

Exclusion criteria:

1. serious infection was not controlled before treatment;
2. contraindications for the use of dexitabine and azacytidine;
3. other cases that did not meet the admission criteria.